Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Poze-Cemdi Combo Controls Intravascular Hemolysis in PNH Patients Vs Ravulizumab
Details : Veopoz (pozelimab) is a complement C5 inhibitor antibody, which is being evaluated in combination with cemdisiran for the treatment of paroxysmal nocturnal hemoglobinuria.
Product Name : Veopoz
Product Type : Antibody
Upfront Cash : Inapplicable
December 07, 2024
Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable